First-generation versus second-generation drug-eluting stents in patients with chronic kidney disease: a systematic review and meta-analysis

References

• Tsai TT, Messenger JC, Brennan JM, et al. Safety and efficacy of drug-eluting stents in older patients with chronic kidney disease: a report from the linked cathpci registry-cms claims database. J Am Coll Cardiol. 2011;58:1859–1869.
   PubMed Web of Science ®Google Scholar
• Yasuda K, Kasuga H, Aoyama T, et al. Comparison of percutaneous coronary intervention with medication in the treatment of coronary artery disease in hemodialysis patients. J Am Soc Nephrol. 2006;17:2322–2332.
   PubMed Web of Science ®Google Scholar
• Cheung AK, Sarnak MJ, Yan G, et al. The Hemodialysis (HEMO) study. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int. 2000;58:353–362.
   PubMed Web of Science ®Google Scholar
• Sederholm Lawesson S, Todt T, Alfredsson J, et al. Gender difference in prevalence and prognostic impact of renal insufficiency in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention. Heart. 2011;97:308–314.
   PubMed Web of Science ®Google Scholar
• Coca SG, Krumholz HM, Garg AX, et al. Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. JAMA. 2006;296:1377–1384.
   PubMed Web of Science ®Google Scholar
• Ishio N, Kobayashi Y, Takebayashi H, et al. Impact of drug-eluting stents on clinical and angiographic outcomes in dialysis patients. Circ J. 2007;71:1525–1529.
   PubMed Web of Science ®Google Scholar
• Garg P, Charytan DM, Novack L, et al. Impact of moderate renal insufficiency on restenosis and adverse clinical events after sirolimus-eluting and bare metal stent implantation (from the SIRIUS trials). Am J Cardiol. 2010;106:1436–1442.
   PubMed Web of Science ®Google Scholar
• Okada T, Hayashi Y, Toyofuku M, et al. One-year clinical outcomes of dialysis patients after implantation with sirolimus-eluting coronary stents. Circ J. 2008;72:1430–1435.
   PubMed Web of Science ®Google Scholar
• Mori S, Yasuda S, Kataoka Y, et al. Significant association of coronary artery calcification in stent delivery route with restenosis after sirolimus-eluting stent implantation. Circ J. 2009;73:1856–1863.
   PubMed Web of Science ®Google Scholar
• Natsuaki M, Furukawa Y, Morimoto T, et al. Impact of diabetes on cardiovascular outcomes in hemodialysis patients undergoing coronary revascularization. Circ J. 2011;75:1616–1625.
   PubMed Web of Science ®Google Scholar
• Kedhi E, Joesoef KS, McFadden E, et al. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet. 2010;375:201–209.
   PubMed Web of Science ®Google Scholar
• Onuma Y, Tanimoto S, Ruygrok P, et al. Efficacy of everolimus eluting stent implantation in patients with calcified coronary culprit lesions: two-year angiographic and threeyear clinical results from the SPIRIT II study. Cathet Cardiovasc Interv. 2010;76:634–642.
   PubMed Web of Science ®Google Scholar
• Valenti R, Vergara R, Migliorini A, et al. Comparison of everolimus-eluting stent with paclitaxel-eluting stent in long chronic total occlusions. Am J Cardiol. 2011;107:1768–1771.
   PubMed Web of Science ®Google Scholar
• Park KW, Kang SH, Velders MA, et al. Safety and efficacy of everolimus- versus sirolimus-eluting stents: a systematic review and meta-analysis of 11 randomized trials. Am Heart J. 2013;165:241–250.
   PubMed Web of Science ®Google Scholar
• Navarese EP, Kowalewski M, Kandzari D, et al. First-generation versus second-generation drug-eluting stents in current clinical practice: updated evidence from a comprehensive meta-analysis of randomised clinical trials comprising 31379 patients. Open Heart. 2014;1:e000064.
   PubMedGoogle Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62:e1–e34.
   PubMed Web of Science ®Google Scholar
• Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1–12.
   PubMedGoogle Scholar
• Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. Ottawa: Dept of Epidemiology and Community Medicine, University of Ottawa; 2011 [cited 2018 Jan]. http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm
   Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–188.
   PubMed Web of Science ®Google Scholar
• Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–634.
   PubMed Web of Science ®Google Scholar
• Nishida K, Nakatsuma K, Kawai K, et al. Second-generation versus first-generation drug-eluting stents in patients on hemodialysis. JACC. 2018;71:A1125.
   Google Scholar
• Baber U, Giustino G, Sartori S, et al. Effect of chronic kidney disease in women undergoing percutaneous coronary intervention with drug-eluting stents: a patient-Level pooled analysis of randomized controlled trials. JACC Cardiovasc Interv. 2016;9:28–38.
   PubMedGoogle Scholar
• Crimi G, Leonardi S, Costa F, et al. Role of stent type and of duration of dual antiplatelet therapy in patients with chronic kidney disease undergoing percutaneous coronary interventions. Is bare metal stent implantation still a justifiable choice? A post-hoc analysis of the all comer PRODIGY trial. Int J Cardiol. 2016;212:110–117.
   PubMed Web of Science ®Google Scholar
• Kitasato L, Shimohama T, Ikeda Y, et al. Clinical outcomes of chronic kidney disease patients treated with everolimus-eluting stents (EES) and paclitaxel-eluting stents (PES). Biomed Pharmacother. 2015;72:6–10.
   PubMed Web of Science ®Google Scholar
• Otsuka M, Shiode N, Masaoka Y, et al. Comparison of everolimus- and paclitaxel-eluting stents in dialysis patients. Cardiovasc Revasc Med. 2015;16:208–212.
   PubMed Web of Science ®Google Scholar
• Chan W, Ivanov J, Kotowycz MA, et al. Association between drug-eluting stent type and clinical outcomes in patients with chronic kidney disease undergoing percutaneous coronary intervention. Can J Cardiol. 2014;30:1170–1176.
   PubMed Web of Science ®Google Scholar
• Kamoi D, Ishii H, Kawamura Y, et al. First-generation vs. second-generation drug-eluting stent to coronary intervention in hemodialysis patients. Eur Heart J. Conference: European Society of Cardiology, ESC Congress 2013. Amsterdam Netherlands. 2013;34:164–165.
   PubMed Web of Science ®Google Scholar
• Cho YK, Yoon HJ, Nam CW, et al. 1st drug-eluting stent versus 2nd drug-eluting stent for coronary intervention in dialysis patients. Am J Cardiol. Conference: 18th Annual Interventional Vascular Therapeutics Angioplasty Summit-Transcatheter Cardiovascular Therapeutics Asia Pacific Symposium, TCTAP 2013. Seoul South Korea. 2013;111:79B.
   PubMedGoogle Scholar
• Takimura H, Muramatsu T, Tsukahara R, et al. Paclitaxel prevented the intimal proliferation after percutaneous coronary intervention for patients with renal insufficiency. J Am Coll Cardiol. Conference: 25th Annual Symposium Transcatheter Cardiovascular Therapeutics, TCT 2013. San Francisco, CA United States. 2013;62:B148.
   PubMedGoogle Scholar
• Nakamura S, Ogawa H, Bae JH, et al. The effect of drug-eluting stents on clinical and angiographic outcomes in renal failure patients with dialysis: multicenter registry in Asia. J Am Coll Cardiol. Conference: 24th Annual Symposium of the Transcatheter Cardiovascular Therapeutics, TCT 2012. Miami, FL United States. 2012;60:B42.
   Google Scholar
• Sakakibara T, Ishii H, Toriyama T, et al. Sirolimus-eluting stents vs. everolimus-eluting stent for coronary intervention in patients on chronic hemodialysis. Circ J. 2012;76:351–355.
   PubMed Web of Science ®Google Scholar
• Hachinohe D, Jeong MH, Saito S, et al. Comparison of drug-eluting stents in acute myocardial infarction patients with chronic kidney disease. Korean J Intern Med. 2012;27:397–406.
   PubMed Web of Science ®Google Scholar
• Ahmed K, Jeong MH, Chakraborty R, et al. Coronary stents in patients with ST-elevation myocardial infarction and chronic kidney disease undergoing primary percutaneous coronary intervention. Korean Circ J. 2012;42:830–838.
   PubMed Web of Science ®Google Scholar
• Ishii H, Kumada Y, Toriyama T, et al. Sirolimus-eluting stent vs. everolimus-eluting stent to percutaneous coronary intervention in dialysis patients. Eur Heart J. Conference: European Society of Cardiology, ESC Congress 2011. Paris France. 2011;32:1040.
   Google Scholar
• Camenzind E, Wijns W, Mauri L, et al. Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial. Lancet. 2012;380:1396–1405.
   PubMed Web of Science ®Google Scholar
• Applegate RJ, Yaqub M, Hermiller JB, et al. Long-term (three-year) safety and efficacy of everolimus-eluting stents compared to paclitaxel-eluting stents (from the SPIRIT III Trial). Am J Cardiol. 2011;107:833–840.
   PubMed Web of Science ®Google Scholar
• Jensen LO, Thayssen P, Hansen HS, et al. Randomized comparison of everolimus-eluting and sirolimus-eluting stents in patients treated with percutaneous coronary intervention: the Scandinavian Organization for Randomized Trials with Clinical Outcome IV (SORT OUT IV). Circulation. 2012;125:1246–1255.
   PubMed Web of Science ®Google Scholar
• Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation. 2007;116:85–97.
   PubMed Web of Science ®Google Scholar
• Morel O, El Ghannudi S, Jesel L, et al. Cardiovascular mortality in chronic kidney disease patients undergoing percutaneous coronary intervention is mainly related to impaired p2y12 inhibition by clopidogrel. J Am Coll Cardiol. 2011;57:399–408.
   PubMed Web of Science ®Google Scholar
• Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005;293:2126–2130.
   PubMed Web of Science ®Google Scholar
• Nakano T, Ninomiya T, Sumiyoshi S, et al. Association of kidney function with coronary atherosclerosis and calcification in autopsy samples from Japanese elders: the Hisayama study. Am J Kidney Dis. 2010;55:21–30.
   PubMed Web of Science ®Google Scholar
• Miyagi M, Ishii H, Murakami R, et al. Impact of renal function on coronary plaque composition. Nephrol Dial Transplant. 2010;25:175–181.
   PubMed Web of Science ®Google Scholar
• Jung HH, Kim SW, Han H. Inflammation, mineral metabolism and progressive coronary artery calcification in patients on haemodialysis. Nephrol Dial Transplant. 2006;21:1915–1920.
   PubMed Web of Science ®Google Scholar
• Naidu SS, Selzer F, Jacobs A, et al. Renal insufficiency is an independent predictor of mortality after percutaneous coronary intervention. Am J Cardiol. 2003;92:1160–1164.
   PubMed Web of Science ®Google Scholar
• Lee JM, Kang J, Lee E, et al. Chronic kidney disease in the second-generation drug-eluting stent era: pooled analysis of the Korean multicenter drug-eluting stent registry. JACC Cardiovasc Interv. 2016;9:2097–2109.
   PubMed Web of Science ®Google Scholar
• Bangalore S, Guo Y, Samadashvili Z, et al. Revascularization in patients with multivessel coronary artery disease and chronic kidney disease: everolimus-eluting stents versus voronary artery bypass graft surgery. J Am Coll Cardiol. 2015;66:1209–1220.
   PubMed Web of Science ®Google Scholar
• Appleby CE, Ivanov J, Lavi S, et al. The adverse long-term impact of renal impairment in patients undergoing percutaneous coronary intervention in the drug-eluting stent era. Circ Cardiovasc Interv. 2009;2:309–316.
   PubMed Web of Science ®Google Scholar
• Lemos PA, Serruys PW, van Domburg RT, et al. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the “real world”: the rapamycin-eluting stent evaluated at Rotterdam Cardiology Hospital (Research) registry. Circulation. 2004;109:190–195.
   PubMed Web of Science ®Google Scholar
• Stone GW, Midei M, Newman W, et al. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical followup from the clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions (SPIRIT) III trial. Circulation. 2009;119:680–686.
   PubMed Web of Science ®Google Scholar
• Sarno G, Lagerqvist B, Fröbert O, et al. Lower risk of stent thrombosis and restenosis with unrestricted use of “new-generation” drug-eluting stents: a report from The Nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Eur Heart J. 2012;33:606–613.
   PubMed Web of Science ®Google Scholar
• Stone GW, Rizvi A, Newman W, et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med. 2010;362:1663–1674.
   PubMed Web of Science ®Google Scholar
• Serruys PW, Ruygrok P, Neuzner J, et al. A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: the SPIRIT II trial. EuroIntervention. 2006;2:286–294.
   PubMedGoogle Scholar
• Doostzadeh J, Clark LN, Bezenek S, et al. Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCEV drug-eluting stent. Coron Artery Dis. 2010;21:46–56.
   PubMed Web of Science ®Google Scholar
• Kastrati A, Mehilli J, Dirschinger J, et al. Intracoronary stenting and angiographic results: strut thickness effect on outcome (ISAR-STEREO) trial. Circulation. 2001;103:2816–2821.
   PubMed Web of Science ®Google Scholar
• Silber S, Windecker S, Vranckx P, et al. RESOLUTE all comers investigators. Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE all comers trial. Lancet. 2011;377:1241–1247.
   PubMed Web of Science ®Google Scholar
• Kandzari DE, Leon MB. Overview of pharmacology and clinical trials program with the zotarolimus-eluting endeavor stent. J Interv Cardiol. 2006;19:405–413.
   PubMedGoogle Scholar
• Nakazawa G, Finn AV, John MC, et al. The significance of preclinical evaluation of sirolimus-, paclitaxel-, and zotarolimus-eluting stents. Am J Cardiol. 2007;100:36M–44M.
   PubMed Web of Science ®Google Scholar